Sun Pharmaceutical Industries Chairman Israel Makov to retire on Aug 29

Makov is retiring upon the completion of his current term post the company's Annual General Meeting after having led the Mumbai-based company for ten years

Sun Pharmaceutical
Makov also helped steer the company to pursue its strategy of building a global pipeline of specialty products, Sun Pharma stated.
Press Trust of India New Delhi
1 min read Last Updated : Aug 04 2022 | 1:39 AM IST

Drug major Sun Pharmaceutical Industries on Wednesday said its Chairman Israel Makov will retire from the company on August 29, 2022.

Makov is retiring upon the completion of his current term post the company's Annual General Meeting after having led the Mumbai-based company for ten years.

He was appointed a Board member and the Chairman in 2012.

"Makov has played a significant role in the company's global expansion in the last decade. He guided the company into its next phase of growth with focus on innovation and adoption of newer technologies," Sun Pharma MD Dilip Shanghvi said in a statement.

Under Makov's leadership, Sun Pharma transformed from a USD 1.7 billion organisation focusing on India and the US into the world's fourth largest specialty generic pharmaceutical company operating across 100 plus markets with a turnover of over USD 5 billion, the drug firm said.

Leading the company's global expansion, he guided the acquisition of Ranbaxy in 2014, making Sun Pharma the leader in the Indian pharmaceutical market and a strong player globally, it added.

Makov also helped steer the company to pursue its strategy of building a global pipeline of specialty products, Sun Pharma stated.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CompaniesPharmaceutical companies

First Published: Aug 04 2022 | 1:39 AM IST

Next Story